MindRank AI, a Hangzhou-based biotechnology startup, has successfully secured $52 million in Series B funding to accelerate the clinical development of its therapeutics designed with artificial intelligence. The funding round, backed by a consortium of institutional and healthcare-focused investors, highlights the growing momentum of China’s AI-driven drug discovery sector and its ambition to compete in the lucrative global market for obesity and metabolic disease treatments.
The capital injection will primarily support the advancement of MindRank’s lead candidate, MDR-001, an oral small-molecule glucagon-like peptide-1 receptor agonist (GLP-1RA). According to HealthcareMEA, MDR-001 entered a Phase III clinical trial in China in 2025 for the treatment of obesity and is concurrently under development for type 2 diabetes. The drug’s rapid progression, moving from project initiation to Phase III testing in approximately 4.5 years, underscores the potential efficiency gains offered by AI-native discovery platforms.
MindRank’s core technology is its proprietary Molecule Arts Platform (MAP), an AI-native drug discovery engine that integrates computational biology, chemistry, laboratory experiments, and clinical data into a continuously learning system. “Our goal is to translate advances in computation and AI into better medicines for patients,” said Zhangming Niu, founder and CEO of MindRank, in a statement reported by BioXconomy. “Entering Phase III with MDR-001 is a validation of the AI-first approach to drug discovery.”
Disrupting the Global Obesity Market
The global market for obesity treatments is currently dominated by pharmaceutical giants Eli Lilly and Novo Nordisk, whose injectable therapies—Zepbound (tirzepatide) and Wegovy (semaglutide), respectively—have achieved blockbuster status. However, the industry is aggressively pursuing oral formulations, which offer significant advantages in patient convenience, manufacturing scalability, and supply chain resilience compared to complex injectable biologics.
MindRank’s MDR-001 aims to capture a share of this rapidly expanding market, which GlobalData forecasts will grow at a compound annual growth rate of 32.3 percent through 2031 across major global markets. The clinical data across China’s oral GLP-1 pipeline has been highly encouraging. A Phase II study reported in February 2026 for a triple-receptor agonist co-developed by Novo Nordisk and United Laboratories demonstrated a 19.7 percent weight loss, a figure that exceeds the weight reduction typically associated with injectable Wegovy—setting a high bar for all oral candidates, including MDR-001, now entering Phase III.
The success of MindRank and other Chinese biotech firms in leveraging AI for drug discovery is reshaping the competitive landscape. Insilico Medicine recently posted its first profitable half-year as its own AI-designed drug entered Phase III trials, demonstrating that the AI-first approach can yield both clinical and commercial success. Furthermore, Sanyou Bio and Baiyunshan forged China’s first AI drug discovery alliance in nuclear medicine, indicating that AI is penetrating highly specialized therapeutic areas.
Intensifying Domestic Competition
While MindRank’s progress is notable, the competition within China’s domestic market for next-generation obesity therapies is intensifying rapidly. Several Chinese drug developers are advancing their own oral GLP-1 candidates, creating a crowded and highly competitive clinical pipeline.
In May 2026, Vincentage Pharma reported positive Phase III results for its oral GLP-1RA for obesity. Earlier this month, Hengrui Pharma announced the successful completion of Phase III studies for its GLP-1RA in both obesity and type 2 diabetes. Meanwhile, multinational corporations are not ceding the Chinese market; Novo Nordisk plans to seek regulatory approval in China for its oral Wegovy formulation, and Eli Lilly has already submitted a marketing application for its oral candidate, Foundayo (orforglipron).
To maintain its competitive edge, MindRank is leveraging its MAP engine to expand its metabolic pipeline. Beyond MDR-001, the company is advancing a glucose-dependent insulinotropic polypeptide (GIP) program, a cannabinoid receptor 1 (CB1) candidate, and two undisclosed obesity assets. The company has also secured three investigational new drug (IND) clearances across China and the US and nominated five additional preclinical candidates, including two oncology programs.
The Economics of AI Drug Discovery
One of the most compelling aspects of MindRank’s trajectory is the capital efficiency demonstrated by its AI-driven approach. The company reported that MDR-001 advanced to Phase III, with cumulative research and development spend of approximately $23 million. This figure is a fraction of the hundreds of millions typically required to advance a novel therapeutic candidate to late-stage clinical trials using traditional discovery methods.
“By leveraging our AI computing engine, our team identified a molecule with unique biology and a safety profile faster than traditional methods allow,” Niu said when the Phase III trial was initiated in December 2025. This efficiency is critical for startups competing with multinational pharmaceutical companies that have vastly superior financial resources. By reducing the time and cost of the discovery and preclinical phases, AI platforms enable companies like MindRank to allocate more capital to the expensive, complex clinical trial process.
The $52 million Series B funding will provide MindRank with the necessary runway to execute its pivotal Phase III trial for MDR-001 and continue scaling its MAP platform. As the global pharmaceutical industry increasingly embraces artificial intelligence, the success or failure of candidates like MDR-001 will serve as a crucial bellwether for the viability of the AI-first drug discovery model. If MindRank can successfully navigate the regulatory pathways in China and abroad, it could establish itself as a major player in one of the most consequential therapeutic markets of the decade.